ReviewDrugs2016
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions.
Review in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07215273 (A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219), which is not on this map. Cited by 243 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
Who cites it
243 citing papers in PubMed, 2 syntheses or guidelines pooled it, 497 citations in OpenAlex.
- Liposomal amphotericin B prophylaxis in paediatrics: a systematic review.The Journal of antimicrobial chemotherapy · 2025Pooled it
- Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Frontiers in cellular and infection microbiology · 2022Pooled it
- Fixed Dosing of Liposomal Amphotericin B in Morbidly Obese Individuals.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Trial
- Liposomal amphotericin B-associated electrolyte abnormalities among adult patients in a tertiary hospital.IJID regions · 2026Article
- Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways.Current hypertension reports · 2026Review
- WHO Critical Priority Fungi: A Comprehensive Review of Antifungal Resistance, Emerging Therapeutic Strategies, and the Potential of Antifungal Peptides.International journal of molecular sciences · 2026Review
- Nanomedicine in the Topical Management of Vulvovaginal Candidiasis: An Overview of In Vivo Data.Journal of fungi (Basel, Switzerland) · 2026Review
- Lipid-based nanocarriers for antifungal drug delivery.Discover nano · 2026Review
- Nanotechnology based topical drug delivery systems for psoriasis addressing current strategies clinical progress and manufacturing challenges.Discover nano · 2026Review
- Multi-drug tolerance in Leishmania persister-like cells.Communications biology · 2026Article
- Phenotype-Guided Nanotherapeutic Strategies for Carbapenem-ResistantPharmaceutics · 2026Review
- Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges.International journal of pharmaceutics: X · 2026Review
- First Infant Desensitization to Liposomal Amphotericin B.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026Article
- Liposomal Methylglyoxal Targets Virulence and Intracellular Persistence to Overcome Amphotericin B Resistance inInternational journal of molecular sciences · 2026Article
- Safety and efficacy of echinocandin antifungal agents inAntimicrobial agents and chemotherapy · 2026Article
- Targeting the polyene chain represents an adjuvant strategy for optimizing polyene antifungals.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Candidemia Attributed to a Urinary Tract Source: Retrospective Cohort Study of Risk Factors, Clinical Profiles, Therapeutic Approaches and Outcomes.Mycopathologia · 2026Article
- Article
- Liposomal amphotericin B in the treatment of pediatric gastrointestinal basidiobolomycosis.Journal of medical case reports · 2026Article
- Direct Retrieval of Biomechanical and Hydrodynamic Parameters for Drug Carrier Liposomes Using Conventional Extrusion Processes.ACS omega · 2026Article
183 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Liposomal amphotericin B (AmBisome(®); LAmB) is a unique lipid formulation of amphotericin B. LAmB is a standard of care for a wide range of medically important opportunistic fungal pathogens. LAmB has a significantly improved toxicity profile compared with conventional amphotericin B deoxycholate (DAmB). Despite nearly 20 years of clinical use, the pharmacokinetics and pharmacodynamics of this agent, which differ considerably from DAmB, remain relatively poorly understood and underutilized in the clinical setting. The molecular pharmacology, preclinical and clinical pharmacokinetics, and clinical experience with LAmB for the most commonly encountered fungal pathogens are reviewed. In vitro, experimental animal models and human clinical trial data are summarized, and novel routes of administration and dosing schedules are discussed. LAmB is a formulation that results in reduced toxicity as compared with DAmB while retaining the antifungal effect of the active agent. Its long terminal half-life and retention in tissues suggest that single or intermittent dosing regimens are feasible, and these should be actively investigated in both preclinical models and in clinical trials. Significant gaps remain in knowledge of pharmacokinetics and pharmacodynamics in special populations such as neonates and children, pregnant women and obese patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.